They didn't cure cancer; the compared treatment with their trial drug to a placebo (no drug) and their drug group had significantly better disease-free survival after 1 year than the placebo group. This is typical operating procedure for drug companies trying to get approval for a drug that will compete with an existing drug. Instead of comparing their drug to the existing drug, they compare to placebo. "The patients were randomized to receive extended adjuvant treatment with either neratinib or placebo for a period of one year after completion of adjuvant treatment with Herceptin. The primary endpoint of the trial was disease free survival (DFS). The results of the trial showed that treatment with neratinib resulted in a 33% improvement in DFS versus placebo." The important questions remained unanswered: 1. How would their drug group have compared to a group that continued to take Herceptin for another year? 2. How would the three groups compare after 3 years, or 5 years? For an enlightening and frightening look at the pharmaceutical industry's manipulative tactics check out Anatomy of an Epidemic. And check out these TED talks: http://www.ted.com/talks/ben_goldacre_battling_bad_science/transcript https://www.ted.com/talks/ben_golda...now_about_the_drugs_they_prescribe/transcript
Thank's NoDoji, I am no pharma expert and this thread was just to ask if anyone was lucky to be holding PBYI. There was odd options action on PBYI, Fast Money mentioned PBYI and my stock ARIA. Somebody knew they were going to release that information, can the FDA and Congress really trade on this information?
----A Boston Hedge Fund Made $950 Million On One Stock Today-- http://finance.yahoo.com/news/boston-hedge-fund-just-made-150416042.html